Sun Pharmaceutical Industries gains 3 pct
BofA-ML upgrades the stock to "buy" from "neutral"
Raises target to 1,070 rupees from 960 rupees earlier
Cites integration with Ranbaxy, price hikes at unit Taro and improvement in US supplies as key reason for the upgrade
Sequential improvement in ex-Taro US business, including supply from Halol, is positive; expect further improvement post the completion of remedial measures at Halol, BofA analyst
BofA-ML upgrades the stock to "buy" from "neutral"
Raises target to 1,070 rupees from 960 rupees earlier
Cites integration with Ranbaxy, price hikes at unit Taro and improvement in US supplies as key reason for the upgrade
Sequential improvement in ex-Taro US business, including supply from Halol, is positive; expect further improvement post the completion of remedial measures at Halol, BofA analyst
No comments:
Post a Comment